AI Article Synopsis

  • The study investigates the cancer risks for women with different types of CHEK2 gene variants, particularly focusing on comparisons between monoallelic (one variant) and biallelic (two variants) carriers.
  • Biallelic carriers show significantly higher breast cancer rates (80.6% vs. 41.2%) and are more likely to be diagnosed before age 50 and have multiple breast cancer diagnoses.
  • The findings suggest that women with biallelic CHEK2 pathogenic variants may need more intensive cancer management compared to those with monoallelic variants due to their increased risk.

Article Abstract

Purpose: Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs.

Methods: CHEK2 PV carriers were identified through commercial hereditary cancer panel testing (09/2013-07/2019). We compared cancer histories of 6473 monoallelic carriers to 31 biallelic carriers. Breast cancer risks were estimated using multivariate logistic regression and are reported as odds ratios (OR) with 95% confidence intervals (CI).

Results: Breast cancer frequency was higher among biallelic CHEK2 PV carriers (80.6%, 25/31) than monoallelic carriers (41.2%, 2668/6473; p < 0.0001). Biallelic carriers were more likely to be diagnosed at or before age 50 (61.3%, 19/31) and to have a second breast cancer diagnosis (22.6%, 7/31) compared to monoallelic carriers (23.9%, 1548/6473; p < 0.0001 and 8.1%, 523/6473; p = 0.0107, respectively). Proportionally more biallelic carriers also had any cancer diagnosis and > 1 primary diagnosis. Compared to women with no PVs, biallelic PV carriers had a higher risk of developing ductal invasive breast cancer (OR 8.69, 95% CI 3.69-20.47) and ductal carcinoma in situ (OR 4.98, 95% CI 2.00-12.35) than monoallelic carriers (OR 2.02, 95% CI 1.90-2.15 and OR 1.82, 95% CI 1.66-2.00, respectively).

Conclusions: These data suggest that biallelic CHEK2 PV carriers have a higher risk for breast cancer, are more likely to be diagnosed younger, and to have multiple primary breast cancers compared to monoallelic carriers. Biallelic carriers also appear to have a higher risk of cancer overall. Therefore, more aggressive management may be appropriate for women with biallelic PVs in CHEK2 compared with current recommendations for monoallelic carriers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066089PMC
http://dx.doi.org/10.1007/s10549-020-05543-3DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
biallelic pathogenic
8
pathogenic variants
8
biallelic chek2
8
chek2 carriers
8
monoallelic carriers
8
cancer
6
breast
5
biallelic
5
chek2
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!